HSBC initiated coverage of Teva with a Buy rating and $13 price target. The year of U.S. elections “often can be a source of angst for Biopharma investors,” says the firm, which thinks 2024 will see a heated debate on the impact of drug pricing on the Biopharma industry’s earnings power. In addition, capital allocation and growth beyond patent cliffs is “the second big question the market might have to grapple with is around,” the analyst said in a sector note on Biopharma’s key debates for 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TEVA:
- Teva, Biolojic in pact for developing therapeutic antibodies for inflamation
- Teva put volume heavy and directionally bearish
- Teva announces new post hoc analysis of two Ajovy clinical studies
- Roku upgraded, Lucid Group downgraded: Wall Street’s top analyst calls
- Unusually active option classes on open November 27th